[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bipolar-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bipolar-disorders":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100480545","a-novel-peer-delivered-recovery-focused-suicide-prevention-intervention-for-veterans-with-serious-mental-illness-100480545",false,"NCT05537376","A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness","Inclusion Criteria:\n\nVeteran Inclusion Criteria:\n\n1. Veterans who report present suicidal ideation (i.e., Columbia-Suicide Severity Rating Scale (C-SSRS) \\> 2 (\"Active thoughts of killing oneself\") in past 1 month and\u002For a suicide attempt in the prior 3 months as identified by the C-SSRS\n2. Current SMI diagnosis (i.e., schizophrenia and other psychotic disorders, mood disorders with psychotic features, bipolar disorders)\n3. Capable of informed consent via the University of California San Diego Brief Assessment of Capacity to Consent (UBACC)\n\nPeer Specialist Inclusion Criteria:\n\n1. Certified Peer Specialist employed at VA San Diego Healthcare System (VASDHS) in the Mental Health Care Line (individuals must demonstrate competency in basic suicide screening and referral procedures to be certified)\n2. 2-3 years of experience post certification as a Certified Peer Specialist\n3. Interest in being trained in SUPPORT\n4. Provide verbal or written consent for the research staff to discuss ability to participate in the study with the Peer Specialist's direct clinical supervisor\n5. Direct clinical supervisor agreement to allow the Peer Specialist to participate. This includes the Peer Specialist's direct clinical supervisor agreement to allow the Peer Specialist time as part of their current scope of practice to 1) participate in the full day (8-hour) SUPPORT training, 2) participate in weekly 1-hour group supervision for the duration of the Peer Specialist's time in the study, and 3) take on a case load of at least one SUPPORT Veteran at a given time.\n\nExclusion Criteria:\n\nVeteran Exclusion Criteria:\n\n1. Cannot complete the assessment battery\n2. Current intoxication requiring immediate detoxification or outpatient plan directed specifically to residential substance use disorder (not mental health) services\n3. Imminent psychiatric hospitalization","ALL","18 Years",{"count":18,"type":19},69,"ESTIMATED","INTERVENTIONAL",[22],"NA","Suicide is a major public health concern, particularly among Veterans with serious mental illness (SMI, i.e., psychotic disorders or bipolar disorders). Wellness Recovery Action Plan (WRAP) is a well-established evidence-based practice for those with SMI that centers on identifying warning signs of mental illness, developing wellness tools for functional independence, planning for day-to-day effective living within one's community, and building an action plan to create a valued life worth living. This proposed study will refine and pilot SUicide Prevention by Peers Offering Recovery Tactics (SUPPORT), a novel integrated recovery program that is an adaptation of peer-delivered WRAP for Veterans with SMI. In SUPPORT, a Peer Specialist leads a Veteran at increased risk for suicide through recovery planning that is tailored to the Veteran's suicidal experiences with cognitive learning strategies to enhance safety plan recall and improve functioning.",[25,26,27,28],"Psychotic Disorders","Bipolar Disorders","Suicidal Ideation","Suicide, Attempted","RECRUITING","2025-08-05",{"date":32,"type":33},"2025-08-07","ACTUAL",{"date":35,"type":33},"2023-09-12",{"date":37,"type":19},"2027-10-31",{"name":39,"class":40},"VA Office of Research and Development","FED",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100578971","monpsymoi-a-digital-platform-for-collecting-patient-reported-experience-and-outcome-measures-in-psychiatry-100578971","NCT06818227","MonPsy&Moi: A Digital Platform for Collecting Patient-Reported Experience and Outcome Measures in Psychiatry","MonPsyMoi: Etude Des Conditions d'implémentation et de l'Impact de la Plateforme Digitale française de Recueil de l'expérience Patient en Psychiatrie (Modules Avec et Sans \" Feedback \")","Mon Psy & Moi","Inclusion Criteria:\n\n* Residing in France. Age between 18 and 65 years at the time of inclusion.\n\nReceiving care in one of the 12 participating psychiatric facilities, with a confirmed diagnosis of:\n\nSchizophrenia Spectrum Disorders (e.g., schizophrenia, schizoaffective disorder).\n\nBipolar Disorders. Major Depressive Disorders. A valid email address. Ability to read and understand French. Non-opposition to participating in the study (based on informed consent).\n\nExclusion Criteria:\n\n* Primary diagnosis of an organic mental disorder, including:\n\nDementia. Stroke. Traumatic brain injury. Individuals deprived of liberty by judicial decision (e.g., incarcerated patients).","65 Years",{"count":52,"type":19},23660,"OBSERVATIONAL","Mental health disorders, with a 30% annual prevalence rate, are a leading cause of disability and reduced life expectancy. Despite their impact, patient-reported experience measures (PREMs) and outcome measures (PROMs) are underutilized in psychiatry. MonPsy\\&Moi®, a digital platform funded by ATIH and DGOS, addresses this gap by providing a user-friendly tool to assess patient experiences and outcomes in real-time, aiming to improve the quality of psychiatric care across France.\n\nThe study consists of two stages:\n\nStage 1 (No Feedback): MonPsy\\&Moi® is deployed across 12 psychiatric facilities, collecting patient data without feedback to clinicians. Objectives include assessing implementation feasibility, validating adaptive questionnaires (PREMIUM), and identifying predictors of patient outcomes, such as relapse and healthcare utilization.\n\nStage 2 (With Feedback): Focuses on patients with severe mental illnesses (schizophrenia, bipolar disorders, and major depressive disorders). This stage evaluates the impact of providing PREMs\u002FPROMs feedback to clinicians on relapse rates, healthcare costs, and overall patient outcomes.\n\nMonPsy\\&Moi® uses adaptive questionnaires tailored to psychiatric care, covering key domains such as dignity, information, interpersonal relationships, care environment, and treatment. It also evaluates health-related quality of life, including psychological well-being, autonomy, self-esteem, and social relationships. The platform integrates with national healthcare databases (SNDS) to enhance data analysis and predict patient trajectories.\n\nThe study will involve over 22,000 participants in Stage 1 and 1,100 participants in Stage 2, using a quasi-experimental design to compare feedback and non-feedback strategies. Results aim to demonstrate the feasibility, acceptability, and efficacy of MonPsy\\&Moi® in improving mental health outcomes and guiding national psychiatric care policies.\n\nBy empowering patients and clinicians with actionable insights, MonPsy\\&Moi® aspires to set a new standard for patient-centered mental healthcare in real-world settings",[56,26,57],"Schizophrenia Disorders","Major Depression","NOT_YET_RECRUITING","2025-02-04",{"date":61,"type":33},"2025-02-10",{"date":63,"type":19},"2025-02-02",{"date":65,"type":19},"2026-09-21",{"name":67,"class":68},"Assistance Publique Hopitaux De Marseille","OTHER",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":78,"targetDuration":80,"studyType":53,"phases":4,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":41},"100569548","effects-of-lurasidone-on-left-ventricle-systolic-functions-100569548","NCT06695676","Effects of Lurasidone on Left Ventricle Systolic Functions","Evaluation of Left Ventricle Systolic Functions of Patients On Lurasidone","Lurasidone","Inclusion Criteria:\n\n* Aged 18 to 65 years\n* Diagnosed with schizophrenia or bipolar disorder by the psychiatry clinic of our center and indicated to use lurasidone molecule\n* Hasn't been diagnosed with coronary artery disease, any kind of heart failure or severe valvular disease\n\nExclusion Criteria:\n\n* Patients who do not agree to participate to the trial\n* Patient who do not meet the inclusion criteria",true,{"count":79,"type":19},62,"6 Months","The goal of our study to learn if lurasidone molecule which is used on patients with schizophrenia or bipolar disorder has any cardiotoxic effect.",[83,84,26],"Lurasidone Cardiotoxicity","Schizophrenia Patients",[86,87,75,88],"Global Longitudinal Strain","Cardiotoxicity","antipsychotic drugs","2024-11-17",{"date":91,"type":33},"2024-11-19",{"date":93,"type":19},"2024-11",{"date":95,"type":19},"2025-06-01",{"name":97,"class":68},"Aydin Adnan Menderes University"]